HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic viral hepatitis — Clinical Guidelines

Overview

Chronic viral hepatitis encompasses infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV), affecting over 500 million individuals globally and leading to significant morbidity and mortality through complications like cirrhosis and hepatocellular carcinoma 4.

Diagnosis

Serological Testing: Essential for identifying hepatitis B surface antigen (HBsAg) and antibodies to hepatitis C virus (anti-HCV) 4.

Liver Biopsy: Used for assessing disease activity and fibrosis staging; however, smaller biopsy sizes tend to underestimate severity 5.

Non-Invasive Assessment: Transient elastography recommended for evaluating liver fibrosis in chronic viral hepatitis 2.

Management

Chronic Hepatitis B: Tenofovir as a first-line treatment; mean direct cost for three years of follow-up can be substantial (e.g., 538,293 XOF) 1.

Chronic Hepatitis C: Combination therapy with pegylated interferon and ribavirin shows over 50% sustained response rates 4.

Monitoring and Follow-Up: Regular assessment of fibrosis progression and response to therapy is crucial 4.

Special Populations

Transition of Care: Special attention required during the transition from pediatric to adult gastroenterology for chronic viral hepatitis management 4.

Key Recommendations

Utilize transient elastography for non-invasive assessment of liver fibrosis in chronic viral hepatitis patients (Evidence: Expert opinion) 2.

Consider the economic impact of long-term treatment, such as tenofovir for chronic hepatitis B, when planning patient care (Evidence: Moderate) 1.

Ensure comprehensive monitoring and timely transition of care for pediatric patients with chronic viral hepatitis to adult gastroenterology (Evidence: Expert opinion) 4.

References

1 Ouedraogo K, Toure AO, Bocoum FY, Diallo D, Delamou A, Kouanda S. Evaluation of the direct cost of chronic viral hepatitis B in patients monitored at the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital. BMC gastroenterology 2025. link 2 Kemp W, Levy M, Weltman M, Lubel J. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. Journal of gastroenterology and hepatology 2015. link 3 Penaloza-MacMaster P, Barber DL, Wherry EJ, Provine NM, Teigler JE, Parenteau L et al.. Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection. Science (New York, N.Y.) 2015. link 4 Marcellin P, Boyer N. Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. Best practice & research. Clinical gastroenterology 2003. link00014-3) 5 Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. Journal of hepatology 2003. link00191-0)

Chronic viral hepatitis